DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Chan | ko |
dc.contributor.author | Yang, Hanseul | ko |
dc.contributor.author | Fukushima, Yoko | ko |
dc.contributor.author | Saw, Phei Er | ko |
dc.contributor.author | Lee, Junyeop | ko |
dc.contributor.author | Park, Jin-Sung | ko |
dc.contributor.author | Park, Intae | ko |
dc.contributor.author | Jung, Jinmyung | ko |
dc.contributor.author | Kataoka, Hiroshi | ko |
dc.contributor.author | Lee, Doheon | ko |
dc.contributor.author | Heo, Won Do | ko |
dc.contributor.author | Kim, Injune | ko |
dc.contributor.author | Jon, Sangyong | ko |
dc.contributor.author | Adams, Ralf H. | ko |
dc.contributor.author | Nishikawa, Shin-Ichi | ko |
dc.contributor.author | Uemura, Akiyoshi | ko |
dc.contributor.author | Koh, Gou Young | ko |
dc.date.accessioned | 2014-09-02 | - |
dc.date.available | 2014-09-02 | - |
dc.date.created | 2014-01-24 | - |
dc.date.created | 2014-01-24 | - |
dc.date.created | 2014-01-24 | - |
dc.date.created | 2014-01-24 | - |
dc.date.created | 2014-01-24 | - |
dc.date.issued | 2014-01 | - |
dc.identifier.citation | CANCER CELL, v.25, no.1, pp.102 - 117 | - |
dc.identifier.issn | 1535-6108 | - |
dc.identifier.uri | http://hdl.handle.net/10203/189715 | - |
dc.description.abstract | Current antiangiogenic therapy is limited by its cytostatic nature and systemic side effects. To address these limitations, we have unveiled the role of RhoJ, an endothelial-enriched Rho GTPase, during tumor progression. RhoJ blockade provides a double assault on tumor vessels by both inhibiting tumor angiogenesis and disrupting the preformed tumor vessels through the activation of the RhoA-ROCK (Rho kinase) signaling pathway in tumor endothelial cells, consequently resulting in a functional failure Of tumor vasculatures. Moreover, enhanced anticancer effects were observed when RhoJ blockade was employed in concert with a cytotoxic chemotherapeutic agent, angiogenesis-inhibiting agent, or vascular-disrupting agent. These results identify RhoJ blockade as a selective and effective therapeutic strategy for targeting tumor vasculature with minimal side effects. | - |
dc.language | English | - |
dc.publisher | CELL PRESS | - |
dc.title | Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption | - |
dc.type | Article | - |
dc.identifier.wosid | 000330819900013 | - |
dc.identifier.scopusid | 2-s2.0-84892414410 | - |
dc.type.rims | ART | - |
dc.citation.volume | 25 | - |
dc.citation.issue | 1 | - |
dc.citation.beginningpage | 102 | - |
dc.citation.endingpage | 117 | - |
dc.citation.publicationname | CANCER CELL | - |
dc.identifier.doi | 10.1016/j.ccr.2013.12.010 | - |
dc.embargo.liftdate | 9999-12-31 | - |
dc.embargo.terms | 9999-12-31 | - |
dc.contributor.localauthor | Yang, Hanseul | - |
dc.contributor.localauthor | Lee, Doheon | - |
dc.contributor.localauthor | Heo, Won Do | - |
dc.contributor.localauthor | Kim, Injune | - |
dc.contributor.localauthor | Jon, Sangyong | - |
dc.contributor.localauthor | Koh, Gou Young | - |
dc.contributor.nonIdAuthor | Kim, Chan | - |
dc.contributor.nonIdAuthor | Fukushima, Yoko | - |
dc.contributor.nonIdAuthor | Saw, Phei Er | - |
dc.contributor.nonIdAuthor | Park, Intae | - |
dc.contributor.nonIdAuthor | Jung, Jinmyung | - |
dc.contributor.nonIdAuthor | Kataoka, Hiroshi | - |
dc.contributor.nonIdAuthor | Adams, Ralf H. | - |
dc.contributor.nonIdAuthor | Nishikawa, Shin-Ichi | - |
dc.contributor.nonIdAuthor | Uemura, Akiyoshi | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordPlus | CLINICAL-APPLICATIONS | - |
dc.subject.keywordPlus | DRUG-RESISTANCE | - |
dc.subject.keywordPlus | BLOOD-VESSELS | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | AGENTS | - |
dc.subject.keywordPlus | GTPASE | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | MICROENVIRONMENT | - |
dc.subject.keywordPlus | COMBINATION | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.